Amgen Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared

SG&A Spending Patterns: Amgen Inc. vs. Blueprint Medicines Corporation

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Amgen Inc., a biotech giant, and Blueprint Medicines Corporation, a rising star, offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses have shown a steady increase, peaking at approximately 6.2 billion in 2023, reflecting a 31% rise over the decade. In contrast, Blueprint Medicines, starting from a modest base, has seen its SG&A expenses skyrocket by over 3,600%, reaching nearly 295 million in 2023. This dramatic growth underscores Blueprint's aggressive expansion strategy. While Amgen's spending reflects its established market position, Blueprint's surge highlights its ambitious growth trajectory. This comparison not only reveals the financial dynamics of these companies but also offers insights into their strategic priorities.